Photo of Mikhail ("Misha") Papisov,  PhD

Mikhail ("Misha") Papisov, PhD

Massachusetts General Hospital

Massachusetts General Hospital


papisov@helix.mgh.harvard.edu

Mikhail ("Misha") Papisov, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Radiology, Harvard Medical School
  • Director, Molecular Pharmacology and Pharmacological Imaging Laboratory, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research interests focus on macromolecular drugs, predominantly for cancer therapy.

My research is focused on identifying novel aspects of the in vivo transport mechanisms and, when such aspects are identified, designing macromolecular therapeutic constructs optimized to “ride” on these novel mechanisms to their respective targets. When necessary, the drug development studies include research on relevant factors, such as macromolecule/particle interactions with biological milieu, surface modification (steric protection) and developing new biomaterials and drug release systems.

I have a broad background in macromolecular drug development, with specific training and expertise in chemistry, drug delivery, drug targeting and pharmacology of large molecules and nanoparticles. Two drugs in the development of which my laboratory has participated are presently in clinical trials. XMT-1001, a macromolecular tecan, was developed entirely in my laboratory with intention to deliver a highly hydrophobic derivative of camptothecin to tumors that have low vascular permeability. XMT-1107 combines an antiangiogenic functionality developed by Dr. J. Folkman with a new macromolecular platform developed in my laboratory.

Presently, my work is focused on non-invasive investigation of the solute transport processes mediated by the cerebrospinal fluid. We have found that at least three aspects of the cerebrospinal transport were previously not adequately understood, and our findings open a new opportunity to develop cancer therapeutics targeted to meningeal and CNS cancer through cerebrospinal delivery route in spite of the known inefficiency of this route for “conventional” therapeutics.

 

Publications

Powered by Harvard Catalyst
  • Papisov MI, Belov VV, Gannon KS. Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. Mol Pharm 2013; 10:1522-32. PubMed
  • Mushti C, Papisov MI. Radioiodination of aryl-alkyl cyclic sulfates. Molecules 2012; 17:13266-74. PubMed
  • Belov VV, Bonab AA, Fischman AJ, Heartlein M, Calias P, Papisov MI. Iodine-124 as a label for pharmacological PET imaging. Mol Pharm 2011; 8:736-47. PubMed
  • Yurkovetskiy A.V., Hiller A., Syed S., Yin M., Lu X.M., Fischman A.J., and Papisov M.I.. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Molecular Pharmaceutics 2004; 1:375-382.
  • Papisov MI, Hiller A, Yurkovetskiy A, Yin M, Barzana M, Hillier S, Fischman AJ. Semisynthetic hydrophilic polyals. Biomacromolecules 2005; 6:2659-70. PubMed
  • Yurkovetskiy A, Choi S, Hiller A, Yin M, McCusker C, Syed S, Fischman AJ, Papisov MI. Fully degradable hydrophilic polyals for protein modification. Biomacromolecules 2005; 6:2648-58. PubMed